Compare ELOG & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELOG | ERNA |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | China | United States |
| Employees | 138 | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 7.8M |
| IPO Year | 2024 | 2021 |
| Metric | ELOG | ERNA |
|---|---|---|
| Price | $0.70 | $4.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.8K | ★ 36.3K |
| Earning Date | 07-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.13 |
| 52 Week High | $3.07 | $15.88 |
| Indicator | ELOG | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 48.48 |
| Support Level | N/A | $4.02 |
| Resistance Level | $0.98 | $4.75 |
| Average True Range (ATR) | 0.07 | 0.40 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 0.00 | 38.93 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.